Inhibitory Effects of a New 1H-Pyrrolo[3,2-c]pyridine Derivative, KIST101029, on Activator Protein-1 Activity and Neoplastic Cell Transformation Induced by Insulin-Like Growth Factor-1

Authors
Yun, Hyo JeongKim, GaramKhanal, PremKim, KaramOh, Chang-HyunChoi, Hoo-KyunSohn, HonglaeChoi, Hong Seok
Issue Date
2013-09
Publisher
PHARMACEUTICAL SOC JAPAN
Citation
BIOLOGICAL & PHARMACEUTICAL BULLETIN, v.36, no.9, pp.1466 - 1473
Abstract
Diarylureas and diarylamides derivatives are reported to have antitumor activity. Encouraged by the interesting antiproliferative activity of diarylurea and diarylamide derivatives, we synthesized a new series of diarylureas and diarylamides containing pyrrolo[3,2-c]pyridine scaffold. In this study, we demonstrate that a N-(3-(4-benzamido-1H-pyrrolo[3,2-c]pyridin-l-yl)phenyl)-4-morpholino-3-(trifluoromethyl)benzamide, KIST101029, inhibits neoplastic cell transformation induced by insulin-like growth factor 1 (IGF-1) in mouse epidermal JB6 C141 cells. The KIST101029 compound inhibited mitogen-activated protein kinase/extracellular signal-regulated kinase kinases (MEK), c-jun N-terminal kinases (JNK), and mechanistic target of rapamycin (mTOR) signaling pathways induced by IGF-1 in JB6 C141 cells, resulting in the inhibition of c-fos and c-mu transcriptional activity. In addition, the KIST101029 inhibited the associated activator protein-1 (AP-1) transactivation activity and cell transformation induced by IGF-1 in JB6 C141 cells. Consistent with these observations, in vivo chorioallantoic membrane assay also showed that the KIST101029 inhibited IGF-1-induced tumorigenicity of JB6 C141 cells. Importantly, KIST101029 suppressed the colony formation of A375 cells in soft agar. Taken together, these results indicate that a KIST101029 might exert chemopreventive effects through the inhibition of phosphorylation of MAPK and mTOR signaling pathway.
Keywords
RECEPTOR TYROSINE KINASES; ADVANCED HEPATOCELLULAR-CARCINOMA; MAP KINASE; MULTIPLE-MYELOMA; RAS ACTIVATION; CANCER; PATHWAYS; MELANOMA; SORAFENIB; MUTATIONS; RECEPTOR TYROSINE KINASES; ADVANCED HEPATOCELLULAR-CARCINOMA; MAP KINASE; MULTIPLE-MYELOMA; RAS ACTIVATION; CANCER; PATHWAYS; MELANOMA; SORAFENIB; MUTATIONS; KIST101029; insulin-like growth factor 1; activator protein-1; cell transformation; c-Fos; c-Jun
ISSN
0918-6158
URI
https://pubs.kist.re.kr/handle/201004/127709
Appears in Collections:
KIST Article > 2013
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE